Table 2. Incremental Costs, Revenues and Outcomes with PCSK9 (Per Patient. Health System’s and Payer’s Perspective) 1/.
| Perspective | ||
|---|---|---|
| Health System | Payer 2/ | |
| Treatment cost (If price = $14,000) | $237,718 | $73,137 |
| Treatment cost (if price = $15,000) | $254,695 | $78,463 |
| Avoided cost (savings) | -$5,800 | -$1,095 |
| Premium revenue | $644 | |
| QALY | 0.66 | |
| Life years | 0.88 | |
| CVD events | -0.41 | |
1/ Effect of PCSK9 on annual probability of CVD is obtained directly from the 1 year effect study of evolocumab.
2/ Private insurance perspective assuming national average premiums, medication copayments and deductibles. It also includes a health insurance turnover rate of 12%.
All costs, revenues and outcomes are per patient and discounted at 3% discount rate.